Correlation Engine 2.0
Clear Search sequence regions


  • cancers (2)
  • chromatin (1)
  • cpg islands (1)
  • glioblastoma (1)
  • glioma (7)
  • IDH (1)
  • lower- grade glioma (1)
  • MIR155HG (13)
  • patient (2)
  • prognostic (2)
  • SP1 (3)
  • stromal cell (1)
  • Sizes of these terms reflect their relevance to your search.

    The lncRNA MIR155 host gene (MIR155HG) plays a role in the progression of several malignant cancers. However, the specific mechanisms of MIR155HG in glioma progression have not been clearly established. The purpose of this study was to investigate the function of MIR155HG in glioma at the transcriptome level and relationship with immune infiltration. Totally, 697 RNA-seq and 594 DNA methylation data were retrieved from The Cancer Genome Atlas (TCGA) dataset while 325 RNA-seq data were retrieved from the Chinese Glioma Genome Atlas (CGGA) dataset. The DNA methylation levels of MIR155HG CpG islands were assessed through bisulfite amplicon sequencing (BSAS). The regulatory mechanism of SP1 on MIR155HG was examined by chromatin immunoprecipitation (ChIP) and luciferase reporter assays. R language was used as the main tool for statistical analysis and graphical work. MIR155HG was predominantly expressed in the isocitrate dehydrogenase (IDH) wild-type as well as mesenchymal subtype gliomas. Promoter methylation levels of MIR155HG in glioblastoma (GBM) were remarkably decreased compared with those in lower-grade glioma (LGG). In addition, there were negative correlations between promoter methylation levels and MIR155HG expressions but positive correlations with patients' overall survival. In vitro studies further revealed that MIR155HG expression was regulated by DNA promoter methylation and transcription factor (SP1) binding to the promoter. Moreover, there was a close association between MIR155HG expression and immune as well as stromal cell infiltrations, inflammatory activities, and immune checkpoints. Clinically, univariate and multivariate Cox analyses revealed that MIR155HG is an independent prognostic marker for glioma patients. Our results established that MIR155HG is a potential biomarker for prognosis and an immunotherapeutic target in glioma. © 2022 Wu et al.

    Citation

    Xuechao Wu, Quan Wan, Jing Wang, Peng Hou, Qijian Zhang, Qing Wang, Xiaojie Lu. Epigenetic Activation of lncRNA MIR155HG Mediated by Promoter Hypomethylation and SP1 is Correlated with Immune Infiltration in Glioma. OncoTargets and therapy. 2022;15:219-235


    PMID: 35299997

    View Full Text